Brief: EyePoint Pharma And Ocumension Therapeutics Announce Approval Of Yutiq By China's NMPA
21/06/2022 14:46
June 21 (Reuters) - Ocumension Therapeutics 1477.HK :
* EYEPOINT PHARMACEUTICALS AND OCUMENSION THERAPEUTICS
ANNOUNCE
APPROVAL OF NEW DRUG APPLICATION BY CHINA’S NMPA FOR YUTIQ® FOR
THE TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE
POSTERIOR SEGMENT OF THE EYE
Source text for Eikon: ID:nGNX9HR5Vk
Further company coverage: 1477.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application